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Interactions of the CHMP protein carboxyl terminal
tails with effector proteins play important roles in
retroviral budding, cytokinesis, and multivesicular
body biogenesis. Here we demonstrate that hydro-
phobic residues at the CHMP4B C-terminal amphi-
pathic a helix bind a concave surface of Brox, a
mammalian paralog of Alix. Unexpectedly, CHMP5
was also found to bind Brox and specifically recruit
endogenous Brox to detergent-resistant membrane
fractions through its C-terminal 20 residues. Instead
of an a helix, the CHMP5 C-terminal tail adopts
a tandem b-hairpin structure that binds Brox at the
same site asCHMP4B. Additional Brox:CHMP5 inter-
face is furnished by a unique CHMP5 hydrophobic
pocket engaging the Brox residue Y348 that is not
conserved among the Bro1 domains. Our studies
thus unveil a b-hairpin conformation of the CHMP5
protein C-terminal tail, and provide insights into the
overlapping but distinct binding profiles of ESCRT-
III and the Bro1 domain proteins.
INTRODUCTION
The endosomal sorting complex required for transport (ESCRT)
machinery plays crucial roles in membrane fission and remodel-
ing events during retroviral budding (Dordor et al., 2011), cytoki-
nesis (Caballe and Martin-Serrano, 2011), multivesicular body
biogenesis (Henne et al., 2011; Hurley, 2010), and autophagy
(Rusten and Stenmark, 2009). In mammalian cells, it consists
of several protein complexes such as ESCRT-0, ESCRT-I,
ESCRT-II, and ESCRT-III, plus the VPS4-LIP5 complex, and
several associated proteins such as the Bro1 domain-containing
proteins Alix, HD-PTP, and Brox (Peel et al., 2011). Among
these, ESCRT-III and VPS4 are the most highly conserved and
essential components, as the former assembles into deter-
gent-resistant polymers to induce membrane scission, and the
latter recycles ESCRT-III into soluble monomers for the nextStructure 20ESCRT cycle (Hurley and Hanson, 2010; Lata et al., 2008b;
Shim et al., 2008).
ESCRT-III family is composed of seven protein families named
charged multivesicular body proteins (CHMP) 1–7 and IST-1
(increased sodium tolerance-1), all of which possess character-
istic bipartite sequences containing basic N-terminal and acidic
C-terminal fragments. Interactions between these two polarized
segments maintain CHMP proteins in self-inhibited states as
soluble monomers (Bajorek et al., 2009; Lata et al., 2008a;
Shim et al., 2007; Zamborlini et al., 2006). Binding of acidic lipids
to the CHMP N-terminal region induces conformational changes
followed by polymerization and exposure of their C-terminal
fragments, which in turn recruit VPS4 and other effector proteins
(Bajorek et al., 2009; Lata et al., 2008a; Shim et al., 2007). CHMP
proteins are known to bind the microtubule-interacting and
transport (MIT) domains of VPS4, Vta1/LIP5, and other effector
proteins through their MIT-interaction motifs (MIMs) with dif-
ferent affinities (Azmi et al., 2008; Kieffer et al., 2008; Row
et al., 2007; Ward et al., 2005). These interactions generally
involve the MIT domain three helix bundles bound to MIMs in
either amphipathic a helices such as those from CHMP1A
(Stuchell-Brereton et al., 2007), CHMP1B (Yang et al., 2008),
Did2 (yeast homolog of CHMP1)(Xiao et al., 2009), Vps2 (yeast
homolog of human CHMP2) (Obita et al., 2007), and CHMP3
(Solomons et al., 2011), or in an extended conformation such
as those from CHMP6 (Kieffer et al., 2008) and its archaea
homolog Saci1372 (Samson et al., 2008). Notably, all of the
a-helical MIMs consist of the C-terminal tails of the respective
CHMP proteins. In addition, the C-terminal tails of CHMP4A, B,
and C isoforms adopt a-helical conformations and bind a
conserved hydrophobic pocket at the Bro1 domain of Alix, which
is involved in retroviral budding (Fisher et al., 2007; McCullough
et al., 2008; Usami et al., 2007). The C-terminal tail of CHMP5
does not have a distinctive amphipathic feature and has not
been reported to be involved in protein complex formation. The
a4-a5 helices of CHMP5, predicted based on the core structure
of CHMP3 (Muzio1 et al., 2006), is associated with the Vta1/LIP5
N-terminal MIT domains (Azmi et al., 2008; Bowers et al., 2004;
Ward et al., 2005; Xiao et al., 2008). This interaction colocalizes
CHMP5 with Vta1 to the endosomes and indirectly potentiates
VPS4 activity to disassemble the ESCRT-III complex (Nickerson
et al., 2010; Shiflett et al., 2004)., 887–898, May 9, 2012 ª2012 Elsevier Ltd All rights reserved 887
Structure
Both CHMP5 and CHMP4B C-Terminal Tails Bind BroxBrox was initially identified as a Bro1 domain-containing
protein that binds CHMP4B and contains a C-terminal CAAX
farnesylation motif (Ichioka et al., 2008). Recently, the Bro1
domain of Brox was demonstrated to adopt a typical boomerang
structure similar to that of Alix, and binds HIV-1 Gag NC domain
in a similar manner, but did not appear to promote HIV-1 release
(Sette et al., 2011; Zhai et al., 2011). Consistent with previous
reports of CHMP4B binding to Bro1 domain-containing proteins
(Doyotte et al., 2008; Ichioka et al., 2008, 2007; Katoh et al.,
2003; Strack et al., 2003), structural comparison and modeling
suggested that the Bro1 domains from Brox and HD-PTP could
bind CHMP4B at the same conserved hydrophobic pockets as
Alix (Sette et al., 2011; Zhai et al., 2011). As Brox is a relatively
new member of the Bro1 domain family, little is known about
its partner proteins other than CHMP4B.
To investigate the interaction of Brox with other components
of the ESCRT-III machinery, we tested binding of Brox to
all known CHMP proteins. Surprisingly, we found that both
CHMP5 and CHMP4B associated with Brox, and the CHMP5
C-terminal tail was required for its specific recruitment of Brox
to membrane fractions. To understand the molecular basis of
the Brox:CHMP5 and Brox:CHMP4B interaction, we determined
the crystal structures of Brox in complex with the C-terminal tails
of CHMP5 and CHMP4B. Structural analysis revealed that the
overall character of the Brox:CHMP5 and Brox:CHMP4B inter-
face is similar, with dominant contribution by hydrophobic
contacts. Unexpectedly, the CHMP5 C-terminal tail adopts
a tandem b-hairpin structure with its second b-hairpin anchored
its interface with Brox, whereas the C-terminal tail of CHMP4B
adopts a canonical a-helical structure representative of all other
CHMP C-terminal tail structures determined to date. The struc-
tures demonstrate that the C-terminal tails of the CHMP proteins
can adopt distinctive conformations that interact with Bro1
domain proteins in versatile modes.
RESULTS
Brox Interacts with Both CHMP4B and CHMP5
Among the seven CHMP proteins, only the CHMP4 isoforms are
known to recruit the Bro1 domain containing proteins to the
ESCRT-III machinery (Ichioka et al., 2008, 2007; Katoh et al.,
2003). It is unclear whether other CHMP proteins also play
a role in this process. To investigate this possibility, we used
Brox in a binding study with all known CHMP proteins. To our
surprise, although no interactions were detected with CHMP1A,
1B, 2A, 2B, 3, 6, and 7 (Figure 1A, left panel), Brox was found
to capture CHMP5 as efficiently as the three CHMP4 isoforms
(Figure 1A, right panel, compare lanes 2, 4, 6, and 8). Because
the ability to bind CHMP4 proteins is one of the main character-
istic that defines Bro1 domain-containing proteins such as the
yeast Bro1p and human Alix and HD-PTP (Ichioka et al., 2007;
Katoh et al., 2003; Kim et al., 2005; Odorizzi et al., 2003), we
next asked whether this new Brox:CHMP5 interaction was
specific to Brox or a general property of Bro1-domain containing
proteins. To answer this, we tested the four known human Bro1-
domain containing proteins for their ability to bind CHMP5. In
contrast to Alix, HD-PTP and Rhophilin-2, only Brox was found
in complex with CHMP5 (Figure 1B, lane 2) demonstrating that
the Brox:CHMP5 association is specific.888 Structure 20, 887–898, May 9, 2012 ª2012 Elsevier Ltd All rightsCHMP5 Recruits Endogenous Brox to Cellular
Membranes
ESCRT-III proteins are known to cycle between cytoplasmic
inactive forms (closed conformation) and membrane-bound
active forms (open conformation) where they assemble into
polymers that facilitate membrane fission (Bajorek et al., 2009;
Bodon et al., 2011; Fabrikant et al., 2009; Hanson et al., 2008;
Lata et al., 2008b; Pincetic et al., 2010; Shim et al., 2008). Over-
expression of CHMP proteins triggers the formation of deter-
gent-resistant complexes that can capture binding partners on
cellular membranes (Pincetic et al., 2010; Shim et al., 2007).
To test whether cellular Brox is recruited to membranes by
CHMP5, we performed sedimentation assays, in which cel-
lular extracts are separated into Triton-soluble (S) and Triton-
insoluble (P) fractions (membrane-enriched) as previously
described (Pincetic et al., 2010; Shim et al., 2007). As expected,
endogenous Brox distributed mainly to the cytoplasmic soluble
fraction in the absence of exogenously expressed ESCRT-III
factors (Figure 2A, lanes 1–2). However, expression of CHMP5
dramatically redistributed Brox to the insoluble membrane-
enriched fraction (Figure 2A, lanes 3–4). This suggests that
specific interaction between CHMP5 and Brox recruited the
latter to detergent-resistant membrane fractions. In contrast,
CHMP4Bwas able to recruit both Brox and Alix to themembrane
fractions (Figure S1A available online), consistent with its ability
to interact with both proteins (Ichioka et al., 2008). To further
characterize the interaction of CHMP5 and Brox in the cellular
context, we performed immunofluorescence studies of CHMP5
and Brox. In contrast to Brox alone that exhibited a diffuse cyto-
plasmic staining, coexpression with CHMP5 redistributed Brox
to endosomal-like structures where both proteins colocalized
(Figure 2B, panels a–d). The accumulation of GFP-VPS4A
together with Brox and CHMP5 identified these structures as
class E compartments (Figure 2B, panels e–h). These results
are consistent with our sedimentation assays, and suggest that
the Brox:CHMP5 complex is an integral component of the
ESCRT machinery.
The Brox:CHMP5 Association Requires the C-Terminal
Tail of CHMP5
To map the Brox binding region in CHMP5, we tested their inter-
action using immunoprecipitation assays. The C-terminal tails
of the CHMP4 isoforms were previously shown to recapitulate
the binding of the full-length CHMP4 proteins to the Alix Bro1
domain through hydrophobic residues at successive turns of
their a helices (McCullough et al., 2008), but it was unclear
whether the CHMP5 C-terminal tail functions similarly to those
from CHMP4s in Brox binding. We therefore generated trunca-
tion mutants from the C terminus of CHMP5 and tested their
ability to interact with Brox. Interestingly, removing the last 20
residues of CHMP5 (CHMP5 1–199) was sufficient to abrogate
its interaction with Brox (Figure 2C, lane 3). This suggests that
CHMP5 contains a new Brox-binding motif within its last 20
amino acid residues.
Because the full-length CHMP5 recruited Brox to detergent-
insoluble membrane fractions, we next tested whether ectopic
expression of the CHMP5 1–199 mutant affected the cellular
distribution of Brox. In contrast to the full-length CHMP5, coex-
pression of the CHMP5 1–199 had no effect on Brox distributionreserved
Figure 1. CHMP5 Is a Binding Partner of Brox
(A) Interactions between Brox and ESCRT-III. FLAG-tagged ESCRT-III proteins were expressed in HEK293T cells in the presence or absence of HA-tagged Brox,
and immunoprecipitation was performed using anti-HA antibody conjugated beads. Both input and immunoprecipitated complexes were visualized by western
blot using the indicated antibodies.
(B) FLAG-tagged CHMP5 was expressed in HEK293T cells in the presence or absence of the indicated HA-tagged Bro1-containing proteins. Immunoprecipi-
tation was performed using anti-HA antibody conjugated beads. Both input and immunoprecipitated complexes were analyzed by western blot using the
indicated antibodies.
Structure
Both CHMP5 and CHMP4B C-Terminal Tails Bind Broxin the Triton-soluble fraction (Figure 2A, compare lanes 3–4 and
5–6), even though both the CHMP5 full-length and the truncation
mutant retained their propensity to sediment in the membrane-
enriched pelletable fraction. Therefore, recruitment of Brox to
the membrane-enriched fraction requires specific interaction
with the CHMP5 C-terminal tail. In agreement, the CHMP5
C-tail binds Brox with an affinity comparable to that for the
Brox:CHMP4B interaction (Figure 2D) as measured by a fluores-
cence polarization (FP) assay, and CHMP5 competed with
CHMP4B for association with Brox. This is in contrast to the
Alix Bro1 domain, which binds CHMP4B but has no detectable
affinity for CHMP5 (Figure S1B).
The C-Terminal Tails of the CHMP4B and CHMP5 Adopt
Entirely Different Structures
The CHMP4 C-tails were shown previously to engage the Alix
Bro1 domain through hydrophobic residues (McCullough et al.,
2008), but the spacing of the hydrophobic residues is highly
divergent among the CHMP C-terminal tails (Figure 3A). ToStructure 20illustrate the molecular basis of the Brox interaction with
CHMP5 and CHMP4B, we cocrystallized the Bro1 domain of
Brox in complex with the C-terminal fragments of CHMP5 or
CHMP4B and determined their structures (Table 1). As ex-
pected, the Brox:CHMP4B crystal structure shows that the
C-terminal tail of CHMP4B adopts an amphipathic a-helical
conformation bound to a pocket at the concave side of the
Brox structure (Figures 3B and S2A). Similar to the structure of
Alix:CHMP4B complex (McCullough et al., 2008), the CHMP4B
hydrophobic residues M214, L217, W221, and M224 at succes-
sive turns of the a helix contact Brox residues from the a5,
a6, and a7 helices, and the long C-terminal loop (Figures 4A
and S3). Comparison of the Brox structures in the presence
and absence of CHMP4B reveals a large conformational change
near residue Y348, with its Ca atom shifted 6 A˚ (Figure S3B).
This is largely due to the presence of the CHMP4B residue
M214 that protrudes from the a helix and interacts with hydro-
phobic residues L208, L212, and Y348 in Brox. This in effect
pushes the Y348 loop away from the body of the boomerang, 887–898, May 9, 2012 ª2012 Elsevier Ltd All rights reserved 889
Figure 2. CHMP5 Recruits Brox to VPS4A-
Positive Endosomes and the CHMP5 C-
Tail Is Essential for Brox:CHMP5 Interaction
(A) CHMP5 recruits Brox to cellular membranes.
HEK293T cells were transfected with empty vector
(lanes 1–2), FLAG-tagged CHMP5 FL (lanes 3–4),
or 1–199 (lanes 5–6). Forty-eight hours post-
transfection, cells were lysed and fractionated into
soluble (S) and pellet (P) fractions as described in
Experimental Procedures. Distribution of FLAG-
tagged ESCRT-III and endogenous Brox was
analyzed by western blot using the indicated anti-
bodies. a-tubulin was used as a control protein for
the soluble fraction.
(B) Brox and CHMP5 colocalize to VPS4A-positive
endosomes. HA-tagged Brox was expressed
in HEK293T cells alone (a), with FLAG-tagged
CHMP5 (b–d) or in combination with both FLAG-
tagged CHMP5 and GFP-tagged VPS4A (e–h).
Cells were immunostained as described in Exper-
imental Procedures. Brox, CHMP5, and GFP-
VPS4A are stained turquoise, red, and green,
respectively. Merge panels show colocalization of
Brox and CHMP5 (d) or Brox, CHMP5 and VPS4A
(h) in white. Scale bar represents 5 mm.
(C) The Brox binding site maps to the last 20
residues of CHMP5. FLAG-tagged CHMP5 full-
length (FL, 1–219) or the C-terminal truncated
fragment (1–199) was expressed in HEK293T cells
in the presence or absence of the HA-tagged
Brox. Examination of the protein interactions was
performed similar to (A).
(D) Both CHMP4B and CHMP5 C-tails bind Brox.
The C-tails of CHMP4B and CHMP5 bind Brox
with dissociation constants of 14.3 ± 1.4 mM
(black) and 8.1 ± 2.5 mM (blue), respectively, as
measured by the FP assay. CHMP5 competes
with CHMP4B for binding to Brox (insert) with an
IC50 of 49.9 mM.
See also Figure S1.
Structure
Both CHMP5 and CHMP4B C-Terminal Tails Bind Broxstructure. Both residues L208 and L212 of Brox were previously
reported to be important for CHMP4B binding by Popov et al.
(2009), and similar mode of interaction was observed between
the same CHMP4B residue M214 and the Alix Bro1 domain resi-
dues I212 and L216 (McCullough et al., 2008) (Figure 4B).
As the structures for all CHMPC-terminal tails reported to date
adopt a-helical conformation, we were surprised to find that the
C-terminal tail of CHMP5 adopts a tandem b-hairpin structure
with three short b strands (Figures 3C and S2C). Both of the
b-hairpins belong to a common 3:5 type composed of a classic
type I b-turn and a G1 b-bulge at residues G205 and G212,
respectively (Pantoja-Uceda et al., 2006; Richardson, 1981;
Sibanda et al., 1989) (Figures 5A and S4). The patterns of the
main-chain hydrogen bonds are identical for the two b-hairpins,
with one hydrogen bond between the carbonyl oxygen of residue
i and the amide nitrogen of residue i+3, and the other hydrogen890 Structure 20, 887–898, May 9, 2012 ª2012 Elsevier Ltd All rights reservedbond between the amide nitrogen of
residue i and the carbonyl oxygen of
residue i+4. The overall structure of the
tandem b-hairpins are stabilized by four
additional main-chain:main-chain andmain-chain:side-chain hydrogen bonds. These include hydrogen
bonds between the carbonyl oxygen of L207 and amide nitrogen
of Q215, and the amide nitrogen of V208 and carbonyl oxygen of
T200 (Figure S4A), as well as the N202 (residue i) side-chain to
G205 (residue i+3) main-chain amide hydrogen bond and D209
(residue i) side-chain to G212 (residue i+3) main-chain amide
hydrogen bond (Figure 5A). The seven Ca atoms of the two
b-hairpins can be superimposed with a root mean-square-
deviation (rmsd) of 0.15 A˚, indicating essentially identical main-
chain conformation.
During structural determination of the Brox-CHMP5 complex,
a second region of positive electron density was observed for
crystals containing the longer ‘‘Broxl’’ form at the convex surface
of the Brox structure (Figure S2B). Residues T384 to P394 were
then built in the currentmodel for the Broxl-CHMP5 andBroxl-5P
structures (Table 1) based on the close proximity of the density to
AB
C
Figure 3. Brox Binds the C-Terminal Tails of
CHMP4B and CHMP5
(A) The C-terminal tail sequences for selected CHMP
proteins. The sequences for human, mouse and zebrafish
CHMP5, human CHMP4B, 4A, and 4C, and human
CHMP1A, 2A, and 3 C-terminal tails are shown in three
separate groups. Patterns of hydrophobicity are indicated
above each group with ‘‘F’’ denotes hydrophobic residues
and ‘‘x’’ denotes other residues. The hydrophobic residues
involved in interaction with Brox, Alix, and VPS4 are
marked in red for each group. Residues at the two b-turns
of CHMP5 are shown in yellow shade, and those involved
in interaction with Brox residue Y348 are underlined.
(B) Brox and CHMP4B are shown as cyan and magenta
ribbons, respectively. The secondary structures of theBro1
domain and theNandC termini of theCHMP4Bare labeled.
(C) Brox and CHMP5 are shown as light blue and orange
ribbons, respectively. The secondary structures of theBro1
domain and the N and C termini of the CHMP5 are labeled.
See also Figure S2.
Structure
Both CHMP5 and CHMP4B C-Terminal Tails Bind Broxthe last residue P379 of the Bro1 domain, and the characteristic
bulged side chains of P386 and P388 in an extended Brox
C-terminal region. Nonetheless, the current resolution (2.6 A˚)
does not allow for unambiguous determination of the amino
acid side chains, and thus we can not formally exclude the possi-
bility of alternative models.
The Brox:CHMP5 Complex Employs Two Adjacent
Interfaces
Despite the drastic structural differences, CHMP5 binds Brox at
a similar surface as CHMP4B, but engages two adjacent hydro-
phobic surfaces with its second b-hairpin. At the first interface,
the CHMP5 residues F211 and L213 dock onto a pocket formed
by Brox a5 helix (residues K141 and H144), a6 helix and the
following linker (residues T195, R198, A199, and H204), and a7
helix (residue L208). Most of these same Brox residues are also
involved in binding of CHMP4B residuesW220 and L217 (Figures
4A, 4C, and 5B). The third CHMP4B hydrophobic residue
M214 has no equivalence in CHMP5, instead, the Brox residueStructure 20, 887–898, May 9Y348 occupies the same equivalent position
(Figure 4D). It binds a unique pocket in
CHMP5 formed by residues N202, V206, V208,
and P214, constituting an adjacent second
Brox:CHMP5 interface (Figures 4C and 5B).
Remarkably, these Brox-binding residues are
identical among theCHMP5proteins fromzebra-
fish to human, but are not conserved in other
CHMPs (Figure 3A). In addition, the Brox residue
Y348 is not conserved among otherBro1 domain
proteins (Sette et al., 2011; Zhai et al., 2011;
Ichioka et al., 2008), which is consistent with the
specific interaction between Brox and CHMP5
(Figures 1A and S1A). The Brox loop containing
Y348 has the most divergent sequences among
the Bro1 domain-containing proteins, trans-
verses the entire length of theBro1domain struc-
tures, and is longer in Brox than in Alix or HD-PTP
(Sette et al., 2011; Zhai et al., 2011). These obser-
vations suggest that this long C-terminal loop ofthe Bro1 domains may be adaptable to different partner proteins
and confer unique functions to each protein.
The peptide directions are reversed between CHMP4B and
CHMP5 in reference to Brox, such that the major hydrophobic
residues of comparable sizes (F211 from CHMP5 and W220
fromCHMP4B, and L213 fromCHMP5 and L217 from CHMP4B)
occupy the same pockets in Brox (Figure 4D). In contrast to
the Brox:CHMP4B structure, CHMP5 binding does not induce
major structural changes in the Brox C-terminal loop with <2 A˚
shifts of the Ca atoms, suggesting a rigid-body fit between
Brox and CHMP5 (Figure S3D). In total, there are 1,100 A˚2 of
solvent accessible surface are buried at the Brox:CHMP5
C-terminal tail interface, compared with 1,300 A˚2 buried at the
Brox:CHMP4B C-terminal tail interface.
Mutation of the Brox:CHMP5 and Brox:CHMP4B
Interface Residues Compromises Their Interactions
To examine the significance of the Brox:CHMP4B and
Brox:CHMP5 interfaces observed in the crystal structures, we, 2012 ª2012 Elsevier Ltd All rights reserved 891
Table 1. X-Ray Diffraction Data Collection and Structural Refinement
Broxl-CHMP5a Broxl-5Pb Broxs-CHMP5c Broxs-5P Broxl-CHMP4B
Data collection
Space group C2 C2 P212121 P212121 P6122
Unit cell dimensions
a, b, c (A˚) 172.4, 46.0, 68.6 173.3, 46.2, 68.8 68.9, 111.4, 116.3 69.2, 111.4, 116.0 138.2, 138.2, 373.8
a, b, g () 90, 104.5, 90 90, 105.0, 90 90, 90, 90 90, 90, 90 90, 90, 120
Wavelength (A˚) 1.075 1.075 1.075 1.075 1.075
Resolution (A˚) 50.0–2.6 50.0–3.1 50.0–2.7 50.0–2.6 50.0–3.8
(Last shell) (2.7–2.6) (3.2–3.1) (2.8–2.7) (2.7–2.6) (3.9–3.8)
Reflections (total/unique) 54,848/15,918 34,035/9,731 97,052/23,032 116,969/27,011 95,231/21,693
Completeness (%) 97.4 (83.9)d 99.2 (94.8)d 91.6 (93.6)d 94.0 (89.2)d 99.3 (98.4)d
I/s(I) 8.7 (1.8)d 6.1 (1.9)d 7.1 (2.4)d 9.0 (2.8)d 18.3 (2.2)d
Rmerge (%)
e 8.45 (57.0)d 12.5 (63.0)d 13.3 (65.9)d 9.8 (39.2)d 3.61 (55.0)d
Refinement
Protein atoms 3,237 3,244 6,238 6,238 3,155
Solvent/hetero-atoms 84/6 22/6 157/6 183/18 0
Rmsd bond lengths (A˚) 0.005 0.007 0.005 0.004 0.006
Rmsd bond angles () 0.969 1.142 0.895 0.863 1.294
Rwork (%)
f 16.6 19.6 18.6 17.7 23.3
Rfree (%)
g 21.1 25.1 25.1 24.1 24.4
Ramachandran plot (%)
favored/disallowedh
97.0/0.0 95.3/0.0 96.3/0.0 97.3/0.0 96.7/0.0
PDB code 3ULY 3UM0 3UM1 3UM2 3UM3
See also Table S1.
aBroxl is a long form of the human Brox protein (residues 2–411), and CHMP5 represents the C-terminal tail of CHMP5 (residues 151–219).
b5P represents a peptide of the CHMP5 C-terminal 20 residues.
cBroxs is a short form of the human Brox protein (residues 2–377).
dNumbers with asterisks correspond to the last resolution shell.
eRmerge = Sh Si jIi(h)  < I(h) > j / ShSi Ii(h), where Ii(h) and < I(h) > are the ith and mean measurement of the intensity of reflection h.
fRwork = ShkFobs (h)j  jFcalc (h)k / ShjFobs (h)j, where Fobs (h) and Fcalc (h) are the observed and calculated structure factors, respectively. No I/s cutoff
was applied.
gRfree is the R value obtained for a test set of reflections consisting of a randomly selected 5% subset of the data set excluded from refinement.
hValues from MolProbity server (http://molprobity.biochem.duke.edu/).
Structure
Both CHMP5 and CHMP4B C-Terminal Tails Bind Broxmutated the interface residues and performed immunoprecipita-
tion and in vitro binding assays to evaluate the interactions
(Figure 6). The Brox residues L208 and L212 are located at its
interface with both CHMP4B and CHMP5, and were previously
reported to be important for Brox:CHMP4B binding (Popov
et al., 2009). In agreement, mutation of these residues resulted
in undetectable binding to both CHMP5 (Figures 6A, left panel,
lane 5, and 6B, left panel) and CHMP4B (Figures 6C, left panel,
lane 5, and 6D, left panel). Similarly, the Brox residues H204
and Y204 are essential for CHMP5 binding (Figures 6A, left
panel, lanes 3 and 4, and 6B, left panel), as H204 form a crucial
hydrogen bond with the main-chain carbonyl oxygen of CHMP5
P214 (Figure 5B), and Y348 engages a largely hydrophobic
pocket formed by four CHMP5 residues (Figure 4C). Neither
H204A nor Y348A appears to be necessary for CHMP4B binding
(Figures 6C, left panel, lanes 3 and 4, and 6D, left panel), because
both are located at the periphery of the Brox:CHMP4B interface
devoid of main-chain contacts or significant hydrophobic in-
teractions (Figure 4A). Importantly, mutation of the CHMP5/
CHMP4B-binding surface residues in Brox did not compromise892 Structure 20, 887–898, May 9, 2012 ª2012 Elsevier Ltd All rightsthe proper folding of the mutants, as shown by their similar CD
spectra to the wild-type Brox protein (Figure S5).
On the CHMP5 side of the interface, mutation of residues F211
and L213 at its first interface with Brox is deleterious to binding,
as well as mutation of P214 at the second interface (Figures 6A,
right panel, lanes 3–5, and 6B, right panel). In comparison, the
CHMP4B residues W220 and L217, binding at the equivalent
Brox surface as residues F211 and L213 from CHMP5, play
essential roles in Brox:CHMP4B association (Figures 6C, right
panel, lanes 4–5, and 6D, right panel). By contrast, M214 at the
peripheral of the interface appears not essential for this interac-
tion (Figures 6C, right panel, lane 3, and 6D, right panel). In
summary, our observations of the Brox:CHMP5/CHMP4B in-
teractions are consistent with our analysis of their crystal
structures.
DISCUSSION
Our structural and biochemical studies show that the C-terminal
tails of both CHMP4B and CHMP5 bind Brox at the same site,reserved
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second Brox:CHMP5 interface centered at Y348 is indi-
cated with a dotted circle. Identical interface residues in
both Brox:CHMP4B (A) and Brox:CHMP5 structures are in
bold and italic. For clarity, the CHMP5 residues T200,
K201, and I216 are omitted.
(D) The Brox:CHMP4B and Brox:CHMP5 structures
are superimposed, and the CHMP4B and CHMP5 are
represented as magenta and orange Ca traces. The
three hydrophobic residues M214, L217, and W220 from
CHMP4B, and the two hydrophobic residues F211 and
L213 from CHMP5, as well as residue Y348 from Brox in
the Brox:CHMP5 structure, are shown inmagenta, orange,
and light blue sticks, respectively.
See also Figure S3.
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Both CHMP5 and CHMP4B C-Terminal Tails Bind Broxbut employ entirely different conformations to posit two equiva-
lent hydrophobic residues at the interface. Reorganization of
the Brox loop near residue Y348 accommodates the third hydro-
phobic residue M214 from CHMP4B, whereas a unique CHMP5
hydrophobic pocket binds the Brox residue Y348 at an equiva-
lent location as the CHMP4B residueM214. Importantly, interac-
tion of Brox with the CHMP5 C-terminal tail is essential for
recruitment of Brox to detergent-resistant membrane fractions,
whichmay be relevant to its function during membrane remodel-
ing events. This work not only provides insights into the ESCRT-
III and Bro1 domain interactions, but also lays the groundwork
for future investigation of the unique functions of the CHMP4
and CHMP5 proteins through their overlapping but distinct
binding profiles to the Bro1 domain proteins.
This work identifies CHMP5 as a partner for Brox, adopts
a tandem b-hairpin structure at its C-terminal tail, and binds
Brox at a similar site as CHMP4B but with reversed peptide
directions. b-hairpins are the simplest super-secondary struc-
tures that are abundant in globular protein structures (Sibanda
and Thornton, 1985). Because of their frequent occurrence at
the hotspots of protein:protein interface, there is intense interest
in the design of b-hairpins or their mimetics as potential thera-
peutic agents (Pantoja-Uceda et al., 2006; Robinson, 2008). In
fact, the first example of a designed b-hairpin has a sequenceStructure 20, 887–898, May 9of NPDG very similar to the first b-turn of the
CHMP5 C-terminal tail (Blanco et al., 1993).
Analysis of the CHMP5 C-terminal tail sequence
suggests that it is in keeping with previous
statistical analysis of b-turn preferences (Hutch-inson and Thornton, 1994). In addition, the CHMP5 C-terminal
fragment is dominated by branched/hydrophobic residues that
favor b- instead of a-secondary structures (Minor and Kim,
1994). Therefore, the tandem b-hairpin structure of the CHMP5
C-terminal tail is dictated by its amino acid sequence. Single
and tandem b-hairpin structures have been identified previously
in the nuclear receptor PPARg, methyltransferase, g-chymo-
trypsin, the Sindbis virus capsid protein, and the WW domains
(Figures S4B–S4G) (Efimov, 1992; Ilsley et al., 2002). Notably,
the WW domains are known to be one of the smallest and
most adaptable mediators of protein-protein interactions (Ilsley
et al., 2002), which parallels the critical involvement of the
b-hairpins at the Brox:CHMP5 interface.
This study identified Brox as the second interacting partner for
CHMP5 described to date, and provides a starting point to
address the functional significance of the Brox:CHMP5 interac-
tion. Our understanding of CHMP5/Vps60 function in eukaryotic
cells has been limited to its role in regulating VPS4 function in
a number of cellular processes via binding its other cellular
partner, LIP5/Vta1 (Azmi et al., 2008; Shiflett et al., 2004; Ward
et al., 2005). Even though CHMP5 is not strictly essential for
the function of ESCRT-III in membrane scission and MVB
biogenesis, it plays an essential role in regulating the function
of late endosomes and lysosomes: CHMP5 deficiency caused, 2012 ª2012 Elsevier Ltd All rights reserved 893
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(A) The two b-hairpins from CHMP5 are superimposed and represented as
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Hydrogen bonds are shown with green dotted lines. Residues in the b-turns
are denoted with i to i+4, according to conventions by Sibanda et al. (1989).
(B) Brox and CHMP5 are shown as light blue and orange ribbons with the
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See also Figure S4.
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Both CHMP5 and CHMP4B C-Terminal Tails Bind Broxaccumulation of late endosome compartments, and enhanced
cell surface receptor signaling due to diminished receptor turn-
over, and was embryonically lethal (Shim et al., 2006). In addi-
tion, CHMP5 was shown to be essential for spindle formation
during mitosis and was found to localize at the midbody during
cytokinesis, suggesting its broad participation in cell division
(Morita et al., 2010, 2007). Furthermore, CHMP5 was reported
to play a key role in the initiation of innate immune response
against retroviral infection bymediating posttranslational modifi-
cation of ESCRT-III proteins and blockade of retroviral release
(Kuang et al., 2011). It remains to be determined whether some
of the defects observed in CHMP5-depleted mammalian cells
were a consequence of interference with Brox function. Because
CHMP5 and CHMP4B compete for the same binding site in
Brox, an attractive model would be that CHMP5 participates in894 Structure 20, 887–898, May 9, 2012 ª2012 Elsevier Ltd All rightsdissociating Brox from CHMP4B once the membrane scission
is complete. By using a novel and distinct mode of binding,
Brox appears to have acquired a unique way to regulate and/
or disassemble the CHMP4 proteins by recruiting CHMP5 and
masking a functional interface. This is in contrast to the Alix
Bro1 domain, which binds CHMP4B but has no detectable
affinity for CHMP5, and might be utilizing other modes of regu-
lation for CHMP4 binding and function. For example, the V or
PRD domain of Alix could mask the CHMP4 binding site at
the Alix Bro1 domain in an autoinhibited state (Zhou et al.,
2009). Studies are underway to further understand these
processes.
EXPERIMENTAL PROCEDURES
A full description of the methods is in the Supplemental Experimental
Procedures.
Immunoprecipitation Assay
The mammalian expression vectors for N-terminal HA-tagged human Alix,
Brox, HD-PTP, and Rhophilin-2 were reported previously (Dussupt et al.,
2009). Expression vectors for ESCRT-III proteins were generated by PCR
amplification from cDNA previously described (Dussupt et al., 2009) or
purchased from Open Biosystems (Huntsville, AL) and subcloned into
p3XFLAG-myc-CMV-26 (Sigma, St. Louis, MO). Point mutations were gener-
ated using the Quik-change mutagenesis kit (Stratagene, Santa Clara, CA).
HEK293T cells were transfected using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) with the indicated expression vectors encoding HA- and
FLAG-tagged proteins. Forty-eight hours posttransfection, cell lysates were
precipitated with agarose beads covalently linked to anti-HA mouse mono-
clonal antibody (Sigma). The beads were then extensively washed and eluted
with HA peptide (100 mg/ml; Sigma). Immunoprecipitates and cell lysates
(input fractions) were visualized by SDS-PAGE and western blot with anti-
FLAG or anti-HA antibody (Sigma).
Sedimentation Assay
The sedimentation assay was adapted from previously described protocols
(Pincetic et al., 2010; Shim et al., 2007). HEK293T cells were transfected
with the indicated plasmids and 48 hr posttransfection, cells were harvested
and resuspended in a lysis buffer containing 10 mM Tris-HCl pH 7.5, 10%
sucrose, 1 mM EDTA, 0.1% Triton X-100, and protease inhibitor cocktail.
The soluble (S) and pellet (P) fractions were separated by centrifugation at
10,0003 g for 15 min at 4C. Pellets were resuspended into the same volume
of lysis buffer as the supernatant and sonicated to shear DNA. Equal volumes
of fraction S and P were analyzed by SDS-PAGE and western blot using anti-
FLAG antibody (M2, Sigma), anti-a-tubulin antibody (DM1A, Sigma), and rabbit
antisera to Alix and Brox produced in the Bouamr lab.
Immunofluorescence Microscopy
HEK293T cells were seeded on glass coverslips and transfected with the indi-
cated plasmids using Lipofectamine 2000. Twenty-four hours posttransfec-
tion, the cells were fixed in 3.7% paraformaldehyde in PBS, quenched with
100 mM Glycine in PBS, permeabilized with 0.5% Triton X-100 (Sigma),
and blocked in 1% BSA in PBS. Cells were stained with mouse anti-HA
and rabbit anti-FLAG primary antibodies (Sigma) followed by Alexa 633-
conjugated anti-mouse and Alexa 594-conjugated anti-rabbit secondary anti-
bodies (Invitrogen). Nuclei were counterstained with DAPI. Coverslips were
mounted with ProLong Gold (Invitrogen) and sequential Z-sections
(0.25 mm each) were obtained by confocal microscopy using a Leica SP5
inverted confocal microscope (Leica Microsystems, Exton, PA). Micrographs
were generated using Imaris software (version 7.3, Bitplane AG, Zurich,
Switzerland).
Protein Expression and Purification
The C-terminal fragments of human CHMP5 (residues 151–219) and human
CHMP4B (residues 121–224) were cloned in a modified pET30a(+) vectorreserved
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Figure 6. Characterization of the Brox:
CHMP5 and Brox:CHMP4B Interfaces in
the Cell
(A) Identification of Brox (left panel) and
CHMP5 (right panel) residues important for the
Brox:CHMP5 interaction in the cell. FLAG-tagged
CHMP5 proteins (WT or the indicated mutant)
were expressed in HEK293T cells in the presence
or absence of HA-tagged Brox (WT or the indi-
cated mutant). Forty-eight hours posttransfection,
cells were lysed in RIPA buffer and cleared lysates
were incubated with anti-HA antibody conjugated
beads. Both input and immunoprecipitated com-
plexes were analyzed by western blot using the
indicated antibodies.
(B) Fluorescence polarization assay for the Brox
(left panel) and CHMP5 (right panel) mutants. The
binding isotherms and the dissociation constants
are marked and color-coded.
(C) Identification of Brox (left panel) and
CHMP4B (right panel) residues important for the
Brox:CHMP4B interaction in the cell. FLAG-
tagged CHMP4B proteins (WT or the indicated
mutant) were expressed in HEK293T cells in the
presence or absence of HA-tagged Brox (WT or
the indicated mutant). Examination of the protein
interactions was performed similar to (A).
(D) Fluorescence polarization assay for the Brox
(left panel) and CHMP4B (right panel) mutants. The
binding isotherms and the dissociation constants
are marked and color-coded.
See also Figure S5.
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Both CHMP5 and CHMP4B C-Terminal Tails Bind Brox(EMD Biosciences, San Diego, CA). The expression vector were transformed
into E. coli BL21 (DE3) cells and protein expression was induced with
0.5 mM isopropyl-b-d-thiogalactoside (IPTG) at OD600 = 0.6 and grew over-
night at 15C. Cells were harvested and lysed in a buffer containing 25 mM
Tris-HCl, pH 8.0, 125 mM NaCl, and 10 mM imidazole. Cleared cell lysates
were purified by nickel affinity chromatography with a HisPrep FF 16/10 affinity
column (GE Healthcare Biosciences, Piscataway, NJ). This was followed by
TEV digestion and size-exclusion chromatography, and a second nickel affinity
chromatography in a buffer containing 25 mM Tris-HCl pH 8.0 and 150 mM
NaCl. Two forms of human Brox proteins were used in this study: residues
2–411 and denoted Broxl in Table 1, and residues 2–377 and denoted ‘‘Broxs’’
in Table 1. The Brox and Alix Bro1 domains were expressed and purified as re-
ported previously (Sette et al., 2011) and similar to the above for the CHMP
proteins. Both the Broxl and Broxs forms were used in cocrystallization with
CHMP5, and only the Broxl form was used in cocrystallization with CHMP4B.Structure 20, 887–898, May 9, 2012Crystallization and X-Ray Diffraction Data
Collection
Crystals for the Brox:CHMP4B complex was ob-
tained by mixing purified Broxl form and the
CHMP4B C-terminal fragment at a 1:1.2 molar
ratio and crystallizing with a well solution contain-
ing 0.1 M imidazole buffer at pH 7.2, 15% glycerol,
and 1 M sodium citrate at 4C. The Brox:CHMP5
crystals were obtained bymixing the Brox proteins
and the CHMP5 C-terminal fragment at a 1:1.5
molar ratio and crystallizing with a well solu-
tion containing 0.2 M magnesium acetate, 0.1 M
sodium cacodylate, pH 6.5, and 20% polyeth-
ylene glycol 8000 at 18C. A synthesized peptide
(TKNKDGVLVDEFGLPQIPAS, United Peptides,
Rockville, MD) corresponding to the CHMP5
C-terminal 20 residues (denoted ‘‘-5P’’ in Table 1)
was used to obtain cocrystals with Brox that areessentially identical to those using the 69 residue CHMP5 C-terminal fragment
(denoted ‘‘-CHMP5’’ in Table 1). The crystalswere flash frozen in liquid nitrogen
with 20% glycerol as cryoprotectant. X-ray diffraction data were collected at
beamline 23-ID at the Argonne National Laboratory (Argonne, IL) or beamline
X29 at the Brookhaven National Laboratory (Upton, NY). The diffraction data
were processed with the HKL2000 package (Otwinowski and Miner, 1997).
Structure Determination and Refinement
Structures for the Brox:CHMP4B and Brox:CHMP5 complexes were deter-
mined by molecular replacement with program Phaser (McCoy, 2007) using
the crystal structure of Brox (3R9M) (Sette et al., 2011) as a search model.
Electron density maps calculated with the molecular replacement solutions
showed clear positive densities at the concave surface of the Brox boomerang
structure (Figure S2). The identity of the CHMP4B C-terminal tail was deter-
mined based on the prominent density for the CHMP4B W220 side-chain,ª2012 Elsevier Ltd All rights reserved 895
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Both CHMP5 and CHMP4B C-Terminal Tails Bind Broxthe strong cylinder-shaped density for a helical structure, and the overall
similarity between the Alix:CHMP4B (3C3Q) and Brox:CHMP4B structures
(Figure S2A). The registry of the CHMP5 C-terminal tail was unambiguously
determined based on the identical positive densities calculated with the
CHMP5 C-terminal fragment (-CHMP5) and the 20 residue peptide (‘‘-5C’’),
the prominent density for the F211 side-chain, no side-chain density for the
adjacent G212, and the following LP sequence has a characteristic ring struc-
ture at the Proline main-chain (Figure S2C).
A second region of positive electron density was observed at the convex
surface of the Brox structure for crystals containing the Broxl form only, and
Brox residues T384 to P394 were built in the current model for the Broxl-
CHMP5 and Broxl-5P structures based on the close proximity of the density
to the last residue P379 of the Bro1 domain, and the characteristic bulged
side chains of P386 and P388 in an extended Brox C-terminal region. Nonethe-
less, we can not formally exclude the possibility of alternative models because
the current resolution does not allow for unambiguous determination of the
amino acid side chains. The Brox:CHMP5 structural models were built and
refined using programs COOT (Emsley and Cowtan, 2004) and PHENIX
(Adams et al., 2010), respectively. The Brox:CHMP4 structure was refined
with the deformable elastic network (DEN) approach incorporated in program
CNS (Bru¨nger et al., 1998; Schro¨der et al., 2010). Calculation of the solvent
accessible surface area was carried out using program Areaimol from the
CCP4 program suite (Lee and Richards, 1971; Potterton et al., 2003). All struc-
ture figures were prepared with program PyMOL (Schro¨dinger, LLC.).
Fluorescence Polarization Assay
5-Fluorescein (FAM) labeled peptides (Table S1) (United Biosystems, Rock-
ville, MD) were dissolved in 25 mM Tris-Cl, pH 8.0, and 150 mM NaCl. Purified
wild-type or mutant Broxl protein samples were diluted with the above buffer
and mixed with the 2 nM FAM labeled peptides. The mixtures were assayed
in black 96-well plates with a Molecular Devices Paradigm spectrometer
(Molecular Devices, Sunnyvale, CA). For the CHMP4B and CHMP5 com-
petition assay, 2 nM FAM-labeled CHMP4B peptide and increasing concen-
trations of unlabeled CHMP5 peptide were mixed with 50 mM Brox protein
and the fluorescence polarization was measured. Data were analyzed and
plotted using program GraphPad Prism version 5.0 (GraphPad Software,
San Diego, CA).
Circular Dichroism Spectroscopy
A J-715 spectrometer (Jasco, Easton, MD) was used to measure the circular
dichroism spectra of the wild-type and mutant Brox protein samples in PBS
buffer (pH 7.4) at 0.5 mg/ml. The spectra were acquired from 198 to 260 nm
with a 1 nm stepsize at 20C and the buffer only spectrum was subtracted
from the Brox sample spectra.
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Coordinates and structure factor files have been deposited in the RCSB
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